Shuttle Pharmaceuticals Holdings Inc(SHPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -60.62 | Insider Own | 0.52% | Shs Outstand | 0.6M | Perf Week | 1.44% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -95.35% | Shs Float | 0.6M | Perf Month | -16.55% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 4.02% | Short Float | 6.24% | Perf Quarter | -15.55% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -6.3% | Short Ratio | 0.02 | Perf Half Y | -61.89% |
| Sales | 0.00B | P/B | 0.59 | EPS next 5Y | - | ROA | -126.42% | Short Interest | 0.04M | Perf YTD | -80.39% |
| Book/sh | 6.03 | P/C | 2.06 | EPS past 3/5Y | 61.57% 11.76% | ROE | -326.36% | 52W High | -93.69% ($55.90) | Perf Year | -89.86% |
| Cash/sh | 1.71 | P/FCF | - | Sales past 3/5Y | - | ROIC | -310.93% | 52W Low | 37.01% ($2.58) | Perf 3Y | -99.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.53% | Gross Margin | - | Volatility(W/M) | 5.07% 8.4% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.3 | EPS Q/Q | 94.37% | Profit Margin | - | RSI (14) | 47.14 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.3 | Sales Q/Q | - | SMA20 | -3.06% ($3.64) | Beta | 1.15 | Target Price | - |
| Payout | - | Debt/Eq | 0.06 | Earnings | - | SMA50 | -1.21% ($3.57) | Rel Volume | 0.01 | Prev Close | $3.53 |
| Employees | 2 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | -61.79% ($9.24) | Avg Volume(3M) | 2.12M | Price | $3.53 |
| IPO | 2022/8/31 | Option/Short | No/Yes | Trades | 229 | Volume | 10,767 | Change | - |
Company
SHPH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Shuttle Pharmaceuticals is a US-based clinical-stage oncology biotech specializing in the development of radiation sensitizers, which enhance the effectiveness of radiation therapy. Its lead candidate, Ropidoxuridine, is currently in a Phase 2 clinical trial for glioblastoma, and the company is expanding its business scope through the acquisition of a prostate cancer diagnostic technology and an AI-powered drug discovery platform.
Over the past 1 year, on the lower side
94% below its 1-year high.
SHPH has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 4.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DEXC 0.00%
EWX 0.00%
AVEE 0.00%
DFAE 0.00%
DFEM 0.00%It ranks #4 in the industry
Based on market cap of $2M.
SHPH $2M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is SHPH?
SHPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SHPH?
The market cap of SHPH is approximately $2M, ranking 5,838 within its sector.
What is the 52-week high and low for SHPH?
SHPH has recorded a 52-week high of $55.90 and a low of $2.58.
